ReNeuron Group plc announced that Olav Hellebø is standing down as CEO of the Company and will leave the Company on 28 February 2022. With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.375 GBX | -2.17% | -.--% | -3.57% |
Apr. 17 | ReNeuron Group Reports CFO Resignation | MT |
Apr. 17 | ReNeuron CFO steps down to pursue other opportunities | AN |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.57% | 2.41M | |
+1.96% | 42.59B | |
+8.02% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.19% | 24.81B | |
-24.41% | 18.17B | |
+28.47% | 12.05B | |
-3.26% | 11.7B | |
+6.96% | 11.1B |
- Stock Market
- Equities
- RENE Stock
- News ReNeuron Group plc
- ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022